Carol J. Thiele is Deputy Chief and a Senior Investigator in the Pediatric Oncology Branch in the Center for Cancer Research at the National Cancer Institute. She received her Ph.D. in Immunology at the UCLA School of Medicine. She received a Cancer Research Institute of America and Damon-Runyon-Walter Winchell Cancer Research Fellowships to study molecular genetics in the Genetics Branch at the NCI. Dr. Thiele was a founding editor of Cell Death and Differentiation and has served on the Editorial Boards of Cancer Research and Molecular Cancer Therapeutics. As a Senior Staff Fellow in the Molecular Genetics Section at the NCI’s Pediatric Branch, Dr. Thiele found her research passion in the study of pediatric cancer. She first attended the Third Conference on Advances in Neuroblastoma Research and over the years has served on the Steering and Advisory committees of the ANR. Dr. Thiele’s early research focused on using molecular genetics to distinguish histopathologically indistinguishable “small round blue cells tumors of childhood” and to identify molecular mechanisms mediating differentiation in Neuroblastoma. Her pre-clinical studies provided a rationale to evaluate retinoids in the treatment of neuroblastoma patients, which are now included in standard therapy for patients with high-risk disease. Her studies on TrkB mediated chemoresistance have revealed that inhibitors of the PI3K/AKT pathway can increase chemosensistivity in NB cells. Her current studies are aimed at understanding how the genetic alterations associated with high-risk neuroblastoma lead to dysregulation of the epigenome and surveying the epigenetic landscape of neuroblastoma for novel treatment modalities.